(Q58085028)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22688626%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

title

Bone: the conundrum of glucocorticoid-induced osteoporosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22688626%20AND%20SRC:MED&resulttype=core&format=json

glucocorticoid-induced osteoporosis

4 February 2020

main subject

osteoporosis

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22688626%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

author name string

Steven L. Teitelbaum

series ordinal

1

0 references

publication date

12 June 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22688626%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Endocrinology

4 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22688626%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22688626%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22688626%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

page(s)

451-452

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22688626%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrendo.2012.89

4 February 2020

exact match

0 references

cites work

American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.89

Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.89

Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.89

Glucocorticoids suppress bone formation via the osteoclast

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.89

Glucocorticoid-induced osteoporosis: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.89

Matrix-embedded cells control osteoclast formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.89

Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.89

Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.89

Teriparatide or alendronate in glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.89

A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.89

31 March 2020

Identifiers

DOI

10.1038/NRENDO.2012.89

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22688626%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference